Coherus Biosciences | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 9.61B 6.98B 2025-03
Acadia Pharmaceuticals USD 225.03M 118.93M 2025-03
ALKERMES USD 292.72M 25.42M 2025-03
Alnylam Pharmaceuticals USD 576.11M 122.21M 2025-03
Amarin USD 58.77M 56.06M 2025-03
Amgen USD 6.86B 85M 2025-03
Baxter International USD 3.19B 644M 2024-12
Biogen USD 2.12B 106.5M 2025-03
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
Fujifilm JPY 761.43B 36.34B 2025-03
Gilead Sciences USD 4.43B 687M 2025-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Merck USD 9.66B 1.67B 2025-03
Myriad Genetics USD 224.9M 24.7M 2025-03
Pacira USD 166.93M 4.38M 2025-03
Perrigo USD 964.5M 61.1M 2025-03
Pfizer USD 10.05B 8.12B 2025-03
PTC Therapeutics USD 205.87M 69.79M 2025-03
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Sarepta Therapeutics USD 1.05B 548.51M 2025-03
Teva Pharmaceutical Industries USD 3.37B 402M 2025-03
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12
Xencor USD 75.91M 9.94M 2025-03
Zoetis USD 1.41B 175M 2025-03



Coherus Biosciences Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.